SciELO - Scientific Electronic Library Online

vol.31 issue7Gene therapy: is possible a vaccine for prostate cancer?Treatment of the dysfunction of the pelvic floor author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Actas Urológicas Españolas

Print version ISSN 0210-4806


RODRIGUEZ GARCIA, N. et al. Natural history of metastasic prostate cancer treated with androgen deprivation therapy and secondary hormonal therapy efficiency. Actas Urol Esp [online]. 2007, vol.31, n.7, pp.714-718. ISSN 0210-4806.

Objective: to analyze metastatic prostate cancer progression in patients treated with hormonal blockade as well as second line hormonal treatments outcomes. Patients and Methods: 199 metastatic patients were selected from a 455 hormonal treated patients pool. Time to biochemical progression was studied with Kaplan Meier analysis and patients were stratified according to pathological differentiation. Second line treatment lasting and efficacy were also assessed. Results: 74 patients out of 192 metastatic patients (56.1%) progressed in terms of PSA. Median time to biochemical progression was 1.7 years (1.2-2.3, CI 95%). We did not find stadistical differences on pathological differentiation (p=0.238). Second line treatment’s efficacy, applied to 41 patients was 34.1%, without any stadistical differences among these treatments. Response treatment median time was 6.8 months without stadistical differences among different treatments (p=0.220). Conclusions: hormonal blockade efficacy in metastatic prostate cancer has a limited value in time in our experience. One third of these patients have a limited response to a second line treatment although this response is even shorter in duration.

Keywords : Prostate cancer; Hormonal treatment.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License